MiNK Therapeutics receives Investment Bank Analyst Rating Update
MiNK Therapeutics, Inc. (INKT) reported Q2 EPS of ($0.18), $0.05 better than the analyst estimate of ($0.23).
Investing.com – U.S. stocks were higher after the close on Monday, as gains in the Technology, Consumer Goods and Utilities sectors led shares higher. At the close in NYSE, the...
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
|Average||9.33 (+342.34% Upside)|
|No. of Analysts||3|